SAN DIEGO, April 22, 2025 (GLOBE NEWSWIRE) -- Bio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced a licensing agreement with AstralBio Inc. for a ...
Everyday Health on MSN
A drug combo that includes a GLP-1 may improve psoriasis and psoriatic arthritis symptoms
The results of 2 recent clinical trials combining the GLP-1 drug and the biologic reinforce the benefits of treating obesity and inflammation together.
LOS ANGELES--(BUSINESS WIRE)--Laekna (2105.HK) announced today that the results of: i) the phase I SAD study of LAE102 (an ActRIIA-selective antibody) for the treatment of obesity; and ii) the ...
Obesity is a major public health concern, and effective treatments are still elusive. AMP-activated protein kinase (AMPK) is a crucial regulator of energy homeostasis and has been proposed as a target ...
Lead amylin receptor agonist engineered antibody significantly reduced acute food intake in a mouse model of obesity, comparable to the efficacy of a leading amylin peptide agonist Findings support ...
China’s Harbour BioMed has launched a new biotech to develop bispecific antibodies focused on the holy grail of next-gen obesity meds—reducing body weight without losing muscle mass. The new entity, ...
SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results